Tocilizumab [Avtozma®]
Availability of ACE Drug Guidance
Yes
Biologics Drug Information Overview
No
Subsidy Information and Financing Scheme
No
Active ingredient: Tocilizumab
General information
Subsidy Information and Financing Scheme
Not Applicable
Drug Guidance for Subsidy
The Ministry of Health’s Drug Advisory Committee has recommended:
Baricitinib 2 mg and 4 mg tablets for treating adults with moderately to severely active rheumatoid arthritis;
Tofacitinib 5 mg tablet for treating adults with moderately to severely active rheumatoid arthritis; and
Rituximab biosimilar (Truxima) 500 mg concentrate for infusion for treating adults with severely active rheumatoid arthritis
in line with their registered indications.
Subsidy status
[R] Baricitinib 2 mg and 4 mg tablets and tofacitinib 5 mg tablets are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication.
[R] Baricitinib and tofacitinib should be used in line with the clinical criteria in the MAF checklist for initial and continuing prescriptions for patients with rheumatoid arthritis.
[R] Rituximab biosimilar (Truxima) 500 mg concentrate for infusion is recommended for inclusion on the MOH Standard Drug List (SDL) for the abovementioned indication.
[NR] SDL subsidy and MAF assistance does not apply to any formulations or strengths of tocilizumab, rituximab reference biologic (MabThera) or other rituximab biosimilars (such as Rixathon).
Registered Product(s) Information
Clinical and product info
Clinical info | Product Info |
|---|---|
Information under the Indication, Dosage and Contraindication sections are extracted from the relevant Package Insert/Patient Information Leaflet of the product available on HSA Infosearch. For more information, please refer to the product's Package Insert/ Patient Information Leaflet available on HSA Infosearch (opens in new tab). The information provided is for informational purposes only, and is not exhaustive. The information provided is not a substitute for professional medical advice. Please consult a qualified healthcare provider for any medical advice. | Information available here are product details as registered with the HSA. As this website is updated monthly, please refer to HSA Infosearch (opens in new tab) for the most updated product information. |
Intravenous
AVTOZMA® CONCENTRATE FOR SOLUTION FOR INFUSION 200MG/10ML [SIN17653P]*
AVTOZMA® CONCENTRATE FOR SOLUTION FOR INFUSION 400MG/20ML [SIN17654P]*
AVTOZMA® CONCENTRATE FOR SOLUTION FOR INFUSION 80MG/4ML [SIN17652P]*
* Clinical information is available for this product.
Subcutaneous
AVTOZMA® SOLUTION FOR INJECTION IN PRE-FILLED PEN 162MG/0.9ML [SIN17655P]*
AVTOZMA® SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 162MG/0.9ML [SIN17656P]*
* Clinical information is available for this product.
